risks with glp 1 Study: GLP-1s 'hold promise' for treating a wide range of diseases and health outcomes Research Reveals Potential Risks of

Nutrition still matters while on a GLP1 therapy

Weight-lowering effects of glucagon-like peptide-1 receptor agonists and detection of breast cancer among obese women with diabetes

In a 12-month study, Second Nature members on tirzepatide lost an average of 22.1% of their body weight, with 95% achieving at least 10% weight loss 5

To understand why this goes beyond temporary discomfort, it helps to look at the emerging field of GLP-1 microbiome science , particularly how your gut bacteria respond to these medications and the central role of a bacterium called Akkermansia muciniphila

E The sole use of sliding-scale insulin in the inpatient hospital setting is strongly discouraged

BMJ (2015) 350:g7607